1. Academic Validation
  2. Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

  • Molecules. 2019 Apr 2;24(7):1295. doi: 10.3390/molecules24071295.
Byeong Ill Lee 1 Min-Ho Park 2 Seok-Ho Shin 3 Jin-Ju Byeon 4 Yuri Park 5 Nahye Kim 6 Jangmi Choi 7 Young G Shin 8
Affiliations

Affiliations

  • 1 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 2 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 3 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 4 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 5 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 6 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 7 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
  • 8 College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea. [email protected].
Abstract

Tozadenant is one of the selective adenosine A2a receptor antagonists with a potential to be a new Parkinson's disease (PD) therapeutic drug. In this study, a liquid chromatography-mass spectrometry based bioanalytical method was qualified and applied for the quantitative analysis of tozadenant in rat plasma. A good calibration curve was observed in the range from 1.01 to 2200 ng/mL for tozadenant using a quadratic regression. In vitro and preclinical in vivo pharmacokinetic (PK) properties of tozadenant were studied through the developed bioanalytical methods, and human PK profiles were predicted using physiologically based pharmacokinetic (PBPK) modeling based on these values. The PBPK model was initially optimized using in vitro and in vivo PK data obtained by intravenous administration at a dose of 1 mg/kg in rats. Other in vivo PK data in rats were used to validate the PBPK model. The human PK of tozadenant after oral administration at a dose of 240 mg was simulated by using an optimized and validated PBPK model. The predicted human PK parameters and profiles were similar to the observed clinical data. As a result, optimized PBPK model could reasonably predict the PK in human.

Keywords

A2a receptor antagonist; PBPK modeling; qualification; tozadenant.

Figures
Products